

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 8-K

NEOSE TECHNOLOGIES INC
Form 8-K
May 18, 2001

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 14, 2001

NEOSE TECHNOLOGIES, INC.

(Exact name of issuer as specified in charter)

DELAWARE
(State or Other Jurisdiction
of Incorporation or
Organization)

0-27718
(Commission
file
number)

13-3549286
(I.R.S. Employer
Identification
Number)

102 Witmer Road,
Horsham, Pennsylvania 19044
(Address of principal executive offices)

(215) 441-5890

(Registrant's telephone number, including area code)

Item 5 - Other Events.

As is more fully described in the attached press release that is incorporated herein by reference, on May 18, 2001, Neose Technologies, Inc. announced that its Research and Development Agreement with Bristol-Myers Squibb Company (the "R&D Agreement") has been amended and assigned to Progenics Pharmaceuticals, Inc. The amendment to the R&D Agreement is filed as Exhibit 99.2 to this Current Report on Form 8-K. The summary descriptions of the transaction contained in this report and the press release are qualified in their entirety by reference to the amendment to the R&D Agreement filed as an exhibit hereto.

Item 7 - Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits

Exhibit No.	Description
-----	-----

Edgar Filing: NEOSE TECHNOLOGIES INC - Form 8-K

- 99.1 Neose Technologies, Inc. Press Release dated May 18, 2001
99.2 Amendment No. 1 to Research and Development Agreement,
dated May 14, 2001, between Neose Technologies, Inc. and
the Pharmaceutical Research Institute of Bristol-Myers
Squibb Company.

Signatures

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

NEOSE TECHNOLOGIES, INC.

Date: May 18, 2001

By: /s/ P. Sherrill Neff

P. Sherrill Neff
President, Chief Operating Officer,
and Chief Financial Officer

Index to Exhibits

Exhibit No.	Description
-----	-----
99.1	Neose Technologies, Inc. Press Release dated May 18, 2001
99.2	Amendment No. 1 to Research and Development Agreement, dated May 14, 2001, between Neose Technologies, Inc. and the Pharmaceutical Research Institute of Bristol-Myers Squibb Company.